Skip to main content
Smart Investors Daily
RN

NASDAQ · RNAC

Cartesian Therapeutics, Inc.

Healthcare · Biotechnology

$6.14

Up+$0.25 (+4.24%)

Updated Nov 21, 2026, 12:35 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
222.59M
P/E ratio
-4.64
Dividend yield
0.00%
52-week range
$5.60 – $11.00
Volume
279.91K
Avg. volume
136.97K

Price performance · RNAC

RNAC price history

1M range · 0 trading sessions · Daily adjusted prices

RNAC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RNAC news

The latest Smart Investors Daily articles mentioning RNAC.

RNAC research

Overview

Company profile and research snapshot.

Company profile

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.67
Implied upside
—
Analysts
—
RNAC recent ratings
DateFirmRatingTarget
Nov 19, 2026HC Wainwright & Co.Buy—
Sep 30, 2026HC Wainwright & Co.Buy—
Sep 29, 2026NeedhamBuy—
Aug 18, 2026WedbushOutperform—
Jun 10, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomy

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.